Journal of Clinical Oncology
Articles in this Issue
Baseline telomere length and prediction of cognitive recovery after chemotherapy in patients with breast cancer: An NCORP prospective cohort study.
12149 Background: Chemotherapy-related cognitive impairment (CRCI) affects up to 70% of breast cancer survivors, yet recov...
Cyclin amplification in biliary tract cancer: Integrated profiling to evaluate immune exclusion, drug sensitivity, and prognosis.
4153 Background: The impact of cell cycle regulator amplifications on the tumor microenvironment (TME) and clinical outcom...
Real-world (RW) characteristics, management, and outcomes of genomically defined mismatch repair deficient (MMR-d) and aggressive variant prostate cancer (AVPC).
e17042 Background: AVPC (≥ 2 alterations in PTEN / TP53...
Real-world implementation of an integrated exercise medicine model within routine oncology care.
1577 Background: Exercise is an evidence-based intervention for people with cancer, with demonstrated benefits for physica...
Efficacy and tolerability of talimogene laherparepvec in treatment of solid tumors: A systematic review.
e14554 Background: Talimogene laherparepvec (T-VEC) is an oncolytic virus engineered to selectively replicate within tumor...
A bidirectional cohort study of chemotherapy-targeted alternating therapy on outcomes of third-line metastatic colorectal cancer.
e15607 Background: CSCO guidelines recommend trifluridine/tipiracil (TAS-102) plus bevacizumab as standard third-line ther...
Body mass index as a prognostic factor for trastuzumab deruxtecan efficacy in advanced breast cancer: A multicenter retrospective real-world analysis.
e13078 Background: Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate (ADC), has improved outcomes in HER2-positiv...
The impact of environmental factors and social determinants of health on molecular alterations in a single-center endometrial cancer cohort.
e17634 Background: Molecular classification has become increasingly important in endometrial cancer (EC) management. The P...
Characterization of antibody-drug conjugate target antigen expression in patients with biliary tract cancer.
e15042 Background: Data on antibody–drug conjugates (ADC)s target expression prevalence, intertumoral heterogeneity, conco...
Impact of erythrocytosis on overall survival, thrombotic events, and risk of transformation to AML in patients with myelofibrosis.
e18637 Background: Erythrocytosis is an uncommon phenotype in myelofibrosis (MF), and its association with long-term survi...
Prognostic value of perioperative ctDNA monitoring in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy (NAC) and surgery.
4094 Background: Recent results from a multicenter phase II clinical trial (jRCTs031200094) demonstrated that neoadjuvant...
Serum albumin and toxicity burden in patients with solid tumors receiving tyrosine kinase inhibitors: A real-world cohort study from Saudi Arabia.
e23359 Background: Tyrosine kinase inhibitors (TKIs) are widely used across multiple malignancies; however, treatment-rela...
Clinical fidelity of large language models in chronic myeloid leukemia: A multimodel comparative study.
6585 Background: Large language models (LLMs) are emerging as promising tools for clinical decision-making. These models a...
Burnout among early-career oncologists in Latin America: A regional survey.
9013 Background: Burnout in healthcare professionals negatively impacts patient care, job satisfaction, and personal well-...
Distinct prognostic roles of <i>IDH</i> mutation and high-risk genomic alterations in patients with primary chondrosarcoma.
11550 Background: Prior studies report mixed associations between IDH mutation and survival in chondrosarcoma. We evaluate...
Impact of baseline performance status on survival and toxicity with ipilimumab plus nivolumab: A 10-year institutional experience across solid tumors.
e23340 Background: Dual immune checkpoint blockade with ipilimumab plus nivolumab (Ipi+Nivo) provides durable benefit acro...
Impact of concomitant GLP-1 receptor agonist use on overall survival and chemotherapy-related adverse events in colorectal cancer: A real-world pharmacoepidemiologic cohort study.
3661 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for diabetes and obesit...
Palliative care for advanced cancer: Medicare Advantage and provider networks.
11050 Background: Palliative care is a specialized medical approach to improve symptoms and quality of life for patients w...
Heterogeneity of cancer prevalence in young adults in the post–COVID-19 era: A multicenter real-world analysis.
e22597 Background: COVID-19 exposure has been linked to persistent immune dysregulation, inflammatory signaling, and epige...
Care utilization and inpatient mortality among women younger than 50 years hospitalized with breast cancer: Racial and socioeconomic disparities.
e13757 Background: Racial and socioeconomic disparities in breast cancer outcomes are well recognized, but it remains uncl...
A feasibility and usability study of a virtual exercise platform in patients with non–small cell lung cancer in a large academic center.
e13794 Background: Exercise during cancer treatment improves cardiorespiratory fitness, reduces fatigue, and enhances qual...
Risk of immune-related adverse events from checkpoint inhibitors in cancer patients with autoimmune disease: An emulated target trial.
11120 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by activating the immune system...
Development and external validation of a recursive attention-based multimodal deep learning model (RAMs-NPC) for prognostic stratification in nasopharyngeal carcinoma: A retrospective study.
e18005 Background: Accurate prognostication is essential for personalized therapy in nasopharyngeal carcinoma (NPC), yet c...
Cervical cancer in Armenia: Current situation and challenges.
e17529 Background: In Armenia, cervical cancer (CC) is the fifth most common cancer among women. Among 15 to 44-year-old w...
Pembrolizumab vs nivolumab plus chemotherapy in metastatic gastric cancer: TriNetX propensity score–matched analysis.
e16066 Background: Pembrolizumab and nivolumab are PD-1 inhibitors used with chemotherapy for first-line HER2-negative adv...